instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the outcome of reaction 'Depressed level of consciousness'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
What was the outcome of reaction 'Diarrhoea'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
What was the outcome of reaction 'Erythema'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
What was the outcome of reaction 'Gastroenteritis salmonella'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,382,004 | 2021-08-05 |
What was the outcome of reaction 'Haematemesis'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovering | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
What was the outcome of reaction 'Malaise'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
What was the outcome of reaction 'Nausea'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
What was the outcome of reaction 'Pyrexia'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
What was the outcome of reaction 'Salmonella bacteraemia'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,382,004 | 2021-08-05 |
What was the outcome of reaction 'Somnolence'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
What was the outcome of reaction 'Ulcer'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovering | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
What was the outcome of reaction 'Vomiting'? | Invasive nontyphoidal Salmonella infection in a patient with Roux-en-Y gastric bypass and gastrostomy tube: a case report.
BACKGROUND
Infections with nontyphoidal Salmonella most commonly cause a self-limited gastroenteritis in humans and are the leading source of foodborne illness. In the USA, the incidence of culture... | Recovered | ReactionOutcome | CC BY | 34348776 | 20,436,591 | 2021-08-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Alanine aminotransferase increased'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Aspartate aminotransferase increased'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Febrile neutropenia'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypophosphataemia'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukopenia'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lymphopenia'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pain'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Renal disorder'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urinary tract disorder'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urinary tract infection'. | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | ADO-TRASTUZUMAB EMTANSINE, PERTUZUMAB, RIBOCICLIB, TRASTUZUMAB | DrugsGivenReaction | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
What was the administration route of drug 'ADO-TRASTUZUMAB EMTANSINE'? | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
What was the administration route of drug 'RIBOCICLIB'? | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | Oral | DrugAdministrationRoute | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
What was the administration route of drug 'TRASTUZUMAB'? | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
What was the dosage of drug 'TRASTUZUMAB'? | Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer.
Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additional strategies to prolong responses to anti-HER2 therapies are needed. Precli... | LOADING DOSE | DrugDosageText | CC BY | 34349115 | 16,387,546 | 2021-08-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Type 2 diabetes mellitus'. | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | DOLUTEGRAVIR, LAMIVUDINE, SULFAMETHOXAZOLE\TRIMETHOPRIM, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY-NC | 34349567 | 19,729,365 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vision blurred'. | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | DOLUTEGRAVIR, LAMIVUDINE, SULFAMETHOXAZOLE\TRIMETHOPRIM, TENOFOVIR DISOPROXIL FUMARATE | DrugsGivenReaction | CC BY-NC | 34349567 | 19,729,365 | 2021 |
What was the administration route of drug 'AMLODIPINE BESYLATE'? | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | Oral | DrugAdministrationRoute | CC BY-NC | 34349567 | 19,729,369 | 2021 |
What was the outcome of reaction 'Fatigue'? | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | Recovered | ReactionOutcome | CC BY-NC | 34349567 | 19,729,369 | 2021 |
What was the outcome of reaction 'Glycosuria'? | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | Recovered | ReactionOutcome | CC BY-NC | 34349567 | 19,729,369 | 2021 |
What was the outcome of reaction 'Hyperglycaemia'? | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | Recovered | ReactionOutcome | CC BY-NC | 34349567 | 19,729,369 | 2021 |
What was the outcome of reaction 'Ketonuria'? | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | Recovered | ReactionOutcome | CC BY-NC | 34349567 | 19,729,369 | 2021 |
What was the outcome of reaction 'Polydipsia'? | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | Recovered | ReactionOutcome | CC BY-NC | 34349567 | 19,729,369 | 2021 |
What was the outcome of reaction 'Polyuria'? | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | Recovered | ReactionOutcome | CC BY-NC | 34349567 | 19,729,369 | 2021 |
What was the outcome of reaction 'Proteinuria'? | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | Recovered | ReactionOutcome | CC BY-NC | 34349567 | 19,729,369 | 2021 |
What was the outcome of reaction 'Vision blurred'? | Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy.
Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus aft... | Recovered | ReactionOutcome | CC BY-NC | 34349567 | 19,729,365 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Abdominal tuberculosis misdiagnosed as acute surgical abdomen and carcinomatosis.
Tuberculosis is a major public health problem worldwide. Tuberculosis can be confused with other diseases and its diagnosis is frequently delayed, especially in areas of low prevalence. Abdominal tuberculosis includes involvement of the g... | ETHAMBUTOL HYDROCHLORIDE, FENTANYL, IMIPENEM, ISONIAZID, METRONIDAZOLE, MIDAZOLAM, NOREPINEPHRINE, PYRAZINAMIDE, RIFAMPIN, SODIUM CHLORIDE | DrugsGivenReaction | CC BY | 34349981 | 20,336,995 | 2021 |
What was the dosage of drug 'ETHAMBUTOL HYDROCHLORIDE'? | Abdominal tuberculosis misdiagnosed as acute surgical abdomen and carcinomatosis.
Tuberculosis is a major public health problem worldwide. Tuberculosis can be confused with other diseases and its diagnosis is frequently delayed, especially in areas of low prevalence. Abdominal tuberculosis includes involvement of the g... | 20 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY | 34349981 | 20,336,995 | 2021 |
What was the dosage of drug 'ISONIAZID'? | Abdominal tuberculosis misdiagnosed as acute surgical abdomen and carcinomatosis.
Tuberculosis is a major public health problem worldwide. Tuberculosis can be confused with other diseases and its diagnosis is frequently delayed, especially in areas of low prevalence. Abdominal tuberculosis includes involvement of the g... | 5 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY | 34349981 | 20,336,995 | 2021 |
What was the dosage of drug 'PYRAZINAMIDE'? | Abdominal tuberculosis misdiagnosed as acute surgical abdomen and carcinomatosis.
Tuberculosis is a major public health problem worldwide. Tuberculosis can be confused with other diseases and its diagnosis is frequently delayed, especially in areas of low prevalence. Abdominal tuberculosis includes involvement of the g... | 25 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY | 34349981 | 20,336,995 | 2021 |
What was the dosage of drug 'RIFAMPIN'? | Abdominal tuberculosis misdiagnosed as acute surgical abdomen and carcinomatosis.
Tuberculosis is a major public health problem worldwide. Tuberculosis can be confused with other diseases and its diagnosis is frequently delayed, especially in areas of low prevalence. Abdominal tuberculosis includes involvement of the g... | 10 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY | 34349981 | 20,336,995 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Breech presentation'. | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | HYDROCORTISONE, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34350037 | 21,025,499 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Exposure during pregnancy'. | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | HYDROCORTISONE, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34350037 | 21,025,113 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Foetal exposure during pregnancy'. | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | HYDROCORTISONE, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34350037 | 21,025,499 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oligohydramnios'. | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | HYDROCORTISONE, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34350037 | 21,025,113 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Premature baby'. | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | HYDROCORTISONE, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34350037 | 21,025,499 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Premature delivery'. | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | HYDROCORTISONE, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34350037 | 21,025,113 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | HYDROCORTISONE, PREDNISONE, RITUXIMAB | DrugsGivenReaction | CC BY | 34350037 | 21,025,113 | 2021 |
What was the administration route of drug 'HYDROCORTISONE'? | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | Transplacental | DrugAdministrationRoute | CC BY | 34350037 | 21,025,499 | 2021 |
What was the administration route of drug 'PREDNISONE'? | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | Transplacental | DrugAdministrationRoute | CC BY | 34350037 | 21,025,499 | 2021 |
What was the administration route of drug 'RITUXIMAB'? | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | Transplacental | DrugAdministrationRoute | CC BY | 34350037 | 21,025,499 | 2021 |
What was the outcome of reaction 'Therapeutic product effect incomplete'? | Antisynthetase Syndrome with Severe Interstitial Lung Disease in Pregnancy.
Antisynthetase syndrome is a rare multisystem autoimmune disorder which clinically manifests with myositis, arthritis, interstitial lung disease, Raynaud phenomenon, and skin hyperkeratosis. Lung involvement represents the most severe form of d... | Not recovered | ReactionOutcome | CC BY | 34350037 | 21,025,113 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Recurrent Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma with Meningeal Involvement.
Extranodal natural killer/T-cell lymphoma nasal type (NNKTL) is a type of non-Hodgkin's lymphoma that has been associated with Epstein-Barr virus (EBV). It has an aggressive behavior, known for predilection to metastasize to diff... | DEXAMETHASONE, ETOPOSIDE, IFOSFAMIDE, METHOTREXATE, PEGASPARGASE | DrugsGivenReaction | CC BY | 34350041 | 19,799,660 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nephropathy toxic'. | Recurrent Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma with Meningeal Involvement.
Extranodal natural killer/T-cell lymphoma nasal type (NNKTL) is a type of non-Hodgkin's lymphoma that has been associated with Epstein-Barr virus (EBV). It has an aggressive behavior, known for predilection to metastasize to diff... | DEXAMETHASONE, ETOPOSIDE, IFOSFAMIDE, METHOTREXATE, PEGASPARGASE | DrugsGivenReaction | CC BY | 34350041 | 19,804,766 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | Recurrent Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma with Meningeal Involvement.
Extranodal natural killer/T-cell lymphoma nasal type (NNKTL) is a type of non-Hodgkin's lymphoma that has been associated with Epstein-Barr virus (EBV). It has an aggressive behavior, known for predilection to metastasize to diff... | DEXAMETHASONE, ETOPOSIDE, IFOSFAMIDE, METHOTREXATE, PEGASPARGASE | DrugsGivenReaction | CC BY | 34350041 | 19,799,660 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Recurrent Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma with Meningeal Involvement.
Extranodal natural killer/T-cell lymphoma nasal type (NNKTL) is a type of non-Hodgkin's lymphoma that has been associated with Epstein-Barr virus (EBV). It has an aggressive behavior, known for predilection to metastasize to diff... | DEXAMETHASONE, ETOPOSIDE, IFOSFAMIDE, METHOTREXATE, PEGASPARGASE | DrugsGivenReaction | CC BY | 34350041 | 19,714,771 | 2021 |
What was the dosage of drug 'DEXAMETHASONE SODIUM PHOSPHATE'? | Recurrent Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma with Meningeal Involvement.
Extranodal natural killer/T-cell lymphoma nasal type (NNKTL) is a type of non-Hodgkin's lymphoma that has been associated with Epstein-Barr virus (EBV). It has an aggressive behavior, known for predilection to metastasize to diff... | 40 MG/D GIVEN ON DAYS 2 TO 4 FOR 1 CYCLE | DrugDosageText | CC BY | 34350041 | 19,775,738 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Postprandial hypoglycaemia'. | Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves.
Metformin rarely, if ever, causes hypoglycemia when it is used as labeled. A 55-year-old woman presented to the medicine ward with an altered level of c... | METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34350076 | 19,726,256 | 2021-07 |
What was the administration route of drug 'METFORMIN HYDROCHLORIDE'? | Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves.
Metformin rarely, if ever, causes hypoglycemia when it is used as labeled. A 55-year-old woman presented to the medicine ward with an altered level of c... | Oral | DrugAdministrationRoute | CC BY | 34350076 | 19,731,082 | 2021-07 |
What was the outcome of reaction 'Postprandial hypoglycaemia'? | Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves.
Metformin rarely, if ever, causes hypoglycemia when it is used as labeled. A 55-year-old woman presented to the medicine ward with an altered level of c... | Recovered | ReactionOutcome | CC BY | 34350076 | 19,726,256 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID-19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, ne... | HYDROXYCHLOROQUINE SULFATE | DrugsGivenReaction | CC BY-NC | 34350584 | 20,594,396 | 2021-10 |
What was the administration route of drug 'HUMAN IMMUNOGLOBULIN G'? | Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID-19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, ne... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34350584 | 20,325,842 | 2021-10 |
What was the dosage of drug 'RITUXIMAB'? | Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID-19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, ne... | UNK, MAINTENANCE THERAPY UNTIL NOVEMBER 2020 | DrugDosageText | CC BY-NC | 34350584 | 20,325,842 | 2021-10 |
What was the outcome of reaction 'Condition aggravated'? | Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID-19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, ne... | Recovered | ReactionOutcome | CC BY-NC | 34350584 | 20,594,396 | 2021-10 |
What was the outcome of reaction 'Off label use'? | Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID-19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, ne... | Recovered | ReactionOutcome | CC BY-NC | 34350584 | 20,594,396 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19'. | SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
A 72-year-old immunocompromised man infected with severe acute respiratory syndrome coronavirus 2 received bamlanivimab monotherapy. Viral evolution was monitored in nasopharyngeal and blood samples by melting curve analysis of single-nucleoti... | RITUXIMAB, TOZINAMERAN, VENETOCLAX | DrugsGivenReaction | CC BY | 34352197 | 20,127,755 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
A 72-year-old immunocompromised man infected with severe acute respiratory syndrome coronavirus 2 received bamlanivimab monotherapy. Viral evolution was monitored in nasopharyngeal and blood samples by melting curve analysis of single-nucleoti... | RITUXIMAB, TOZINAMERAN, VENETOCLAX | DrugsGivenReaction | CC BY | 34352197 | 20,127,755 | 2021-10 |
What was the dosage of drug 'TOZINAMERAN'? | SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
A 72-year-old immunocompromised man infected with severe acute respiratory syndrome coronavirus 2 received bamlanivimab monotherapy. Viral evolution was monitored in nasopharyngeal and blood samples by melting curve analysis of single-nucleoti... | DOSE 1, SINGLE | DrugDosageText | CC BY | 34352197 | 20,127,755 | 2021-10 |
What was the outcome of reaction 'COVID-19'? | SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
A 72-year-old immunocompromised man infected with severe acute respiratory syndrome coronavirus 2 received bamlanivimab monotherapy. Viral evolution was monitored in nasopharyngeal and blood samples by melting curve analysis of single-nucleoti... | Recovered | ReactionOutcome | CC BY | 34352197 | 20,127,755 | 2021-10 |
What was the outcome of reaction 'Drug ineffective'? | SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
A 72-year-old immunocompromised man infected with severe acute respiratory syndrome coronavirus 2 received bamlanivimab monotherapy. Viral evolution was monitored in nasopharyngeal and blood samples by melting curve analysis of single-nucleoti... | Recovered | ReactionOutcome | CC BY | 34352197 | 20,127,755 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acne'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dermatitis acneiform'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemorrhage'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Paronychia'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Proteinuria'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Stomatitis'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Transaminases increased'. | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | AFATINIB, BEVACIZUMAB, ERLOTINIB, GEFITINIB | DrugsGivenReaction | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
What was the administration route of drug 'ERLOTINIB'? | The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma.
The aim of this study was to investigate the efficacy of various Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma pa... | Oral | DrugAdministrationRoute | CC BY-NC | 34352999 | 19,717,822 | 2021-08-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'No adverse event'. | New onset ANCA-associated vasculitis in an adolescent during an acute COVID-19 infection: a case report.
SARS-CoV-2 has been found to be exquisitely adept at triggering autoimmunity and multiple new onset autoimmune diseases have been described as a post-infectious complication of COVID-19 infection in the adult popula... | CEFTRIAXONE, METHYLPREDNISOLONE, RITUXIMAB, VANCOMYCIN | DrugsGivenReaction | CC BY | 34353302 | 20,314,796 | 2021-08-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | New onset ANCA-associated vasculitis in an adolescent during an acute COVID-19 infection: a case report.
SARS-CoV-2 has been found to be exquisitely adept at triggering autoimmunity and multiple new onset autoimmune diseases have been described as a post-infectious complication of COVID-19 infection in the adult popula... | CEFTRIAXONE, METHYLPREDNISOLONE, RITUXIMAB, VANCOMYCIN | DrugsGivenReaction | CC BY | 34353302 | 20,314,796 | 2021-08-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disseminated tuberculosis'. | Neuromyelitis optica and concomitant pulmonary tuberculosis: a case report.
BACKGROUND
Concomitant diagnosis of neuromyelitis optica spectrum disease and pulmonary tuberculosis has rarely been reported.
METHODS
We report a case involving a young Tunisian male patient who developed dry cough followed, 2 months later, ... | ETHAMBUTOL HYDROCHLORIDE, ISONIAZID, METHYLPREDNISOLONE, PYRAZINAMIDE, RIFAMPIN | DrugsGivenReaction | CC BY | 34353370 | 19,991,433 | 2021-08-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Optic neuropathy'. | Neuromyelitis optica and concomitant pulmonary tuberculosis: a case report.
BACKGROUND
Concomitant diagnosis of neuromyelitis optica spectrum disease and pulmonary tuberculosis has rarely been reported.
METHODS
We report a case involving a young Tunisian male patient who developed dry cough followed, 2 months later, ... | ETHAMBUTOL HYDROCHLORIDE, ISONIAZID, METHYLPREDNISOLONE, PYRAZINAMIDE, RIFAMPIN | DrugsGivenReaction | CC BY | 34353370 | 19,991,433 | 2021-08-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | Neuromyelitis optica and concomitant pulmonary tuberculosis: a case report.
BACKGROUND
Concomitant diagnosis of neuromyelitis optica spectrum disease and pulmonary tuberculosis has rarely been reported.
METHODS
We report a case involving a young Tunisian male patient who developed dry cough followed, 2 months later, ... | ETHAMBUTOL HYDROCHLORIDE, ISONIAZID, METHYLPREDNISOLONE, PYRAZINAMIDE, RIFAMPIN | DrugsGivenReaction | CC BY | 34353370 | 19,991,433 | 2021-08-06 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Neuromyelitis optica and concomitant pulmonary tuberculosis: a case report.
BACKGROUND
Concomitant diagnosis of neuromyelitis optica spectrum disease and pulmonary tuberculosis has rarely been reported.
METHODS
We report a case involving a young Tunisian male patient who developed dry cough followed, 2 months later, ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34353370 | 19,991,433 | 2021-08-06 |
What was the dosage of drug 'METHYLPREDNISOLONE'? | Neuromyelitis optica and concomitant pulmonary tuberculosis: a case report.
BACKGROUND
Concomitant diagnosis of neuromyelitis optica spectrum disease and pulmonary tuberculosis has rarely been reported.
METHODS
We report a case involving a young Tunisian male patient who developed dry cough followed, 2 months later, ... | UNK (PULSE THERAPY) | DrugDosageText | CC BY | 34353370 | 19,991,433 | 2021-08-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemothorax'. | A case of hemothorax secondary to intrapleural fibrinolytic therapy: Considerations for use of fibrinolytics in high-risk patients.
Indwelling Pleural Catheters (IPC) are increasingly being used for management of recurrent pleural effusions (RPEs). Use of IPC for management of both malignant and non-malignant recurrent... | APIXABAN, HEPARIN SODIUM | DrugsGivenReaction | CC BY-NC-ND | 34354918 | 19,733,854 | 2021 |
What was the administration route of drug 'APIXABAN'? | A case of hemothorax secondary to intrapleural fibrinolytic therapy: Considerations for use of fibrinolytics in high-risk patients.
Indwelling Pleural Catheters (IPC) are increasingly being used for management of recurrent pleural effusions (RPEs). Use of IPC for management of both malignant and non-malignant recurrent... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34354918 | 19,733,854 | 2021 |
What was the administration route of drug 'HEPARIN SODIUM'? | A case of hemothorax secondary to intrapleural fibrinolytic therapy: Considerations for use of fibrinolytics in high-risk patients.
Indwelling Pleural Catheters (IPC) are increasingly being used for management of recurrent pleural effusions (RPEs). Use of IPC for management of both malignant and non-malignant recurrent... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34354918 | 19,733,854 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute erythroid leukaemia'. | Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL.
Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L-MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (L... | AZACITIDINE, MAGROLIMAB | DrugsGivenReaction | CC BY-NC-ND | 34354920 | 19,880,342 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myelodysplastic syndrome'. | Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL.
Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L-MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (L... | AXICABTAGENE CILOLEUCEL, AZACITIDINE, CARBOPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, GEMCITABINE, IFOSFAMIDE, LENALIDOMIDE, MAGROLIMAB, OXALIPLATIN, PREDNISONE, RITUXIMAB, TAFASITAMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34354920 | 19,878,246 | 2021 |
What was the dosage of drug 'AXICABTAGENE CILOLEUCEL'? | Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL.
Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L-MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (L... | UNK, CAR T-CELL THERAPY | DrugDosageText | CC BY-NC-ND | 34354920 | 20,181,118 | 2021 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.